openPR Logo
Press release

NASH Market Insight and Landscape report

05-03-2019 02:34 PM CET | Health & Medicine

Press release from: Thelansis Knowledge Partners

Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development of effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. Thelansis "NASH – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape of disease overview, pathogenesis, and country/region specific current treatment practice

The global non-alcoholic steatohepatitis (NASH) market is estimated ~$2,579 million in 2015, and is expected to cross $39,596 million by the end of 2030, growing at a CAGR of 21.9% from 2015 to 2030 (15 years of markets projections; four years of historical data, one year of current and eleven years of future market projections). North America, ASIA and Europe are the major region reported with a high prevalence & diagnosed patient pool, however US and Canada mutually contributed ~ 52.34 % of the total revenue followed by EU5(Germany, UK, France, Italy and Spain) with 23.67%. NASH is projected to be the leading cause of liver transplantation in the USA in the coming years which will increase overall disease burden within the space. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

The disease segmentation of NASH patient pool further classified and segregated into different stages fibrosis (F0, F1, F2, F3 & F4-Cirrhosis) includes historical, current and projected epidemiology.

The overall market for NASH has been defined on the basis of country-specific current clinical practice includes symptomatic and off-label therapies, patient share and disease burden (treatment cost, compliance, and market access) has been translated into market.

Emerging therapies:
The developmental pathway for therapeutic agents involves navigating multiple complexities that include the non-linear, heterogeneous nature of disease progression, and the limitations in identifying clinically relevant outcomes. The design of each phase of a clinical trial for a potential therapeutic agent is strongly influenced by the drug’s mechanism of action, characteristics of the patient population (F0, F1, F2, F3 & F4-Cirrhosis) influence by trial design. Currently there are multiple players involved in the designing and development of novel therapies such as: Elafibranor (GFT505) : Genfit, Obeticholic Acid (OCA): Intercept Pharmaceuticals, Cenicriviroc (CVC): (Allergan- Tobira), GS-9674, GS-0976: Gilead Sciences, BMS-98603: BMS, MSDC-0602K: Cirius Therapeutics, Emricasan (IDN-6556): Conatus Pharmaceuticals, NGM282: NGM Biopharmaceuticals, IMM-124E : Immuron, Selonsertib: Gilead Sciences, Aramchol_005: Galmed, GR-MD-02: Galectin Therapeutics

Annual cost of therapy:
Due to lack of treatment options, advanced liver diseases associated with NAFLD will be doubles over coming years. Direct healthcare costs in the USA the annual cost of care per NASH patient with private/ public insurance ranges between USD 3, 367 to USD 8,750 considering current treatment options. These costs are significantly higher in case of patients with control other metabolic comorbidities conditions. The European nations majorly EU5 countries are having the cost burden in similar line, however the reference pricing system and generic entry plays a role in controlling the cost burden

http://www.thelansis.com

Contact Person: Prasoon Narang
Contact NO.:+1-13023803552

Thelansis Knowledge Partners
183 Asylum Street Hartfort
CT-06103, US

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NASH Market Insight and Landscape report here

News-ID: 1726497 • Views: 1629

More Releases from Thelansis Knowledge Partners

Charcot–Marie–Tooth_Market Outlook and Competitive Landscape Report 2018 – …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Charcot–Marie–Tooth (CMT) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current clinical practice,
Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current
Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape r …
Report Snapshot:  Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit

All 5 Releases


More Releases for NASH

Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will
Leah Nash new photographer at Gruppe28
Gruppe28 is pleased to announce that Leah Nash joined its international network of high quality photographers. She will be presented exclusively and internationally by the photo agency Gruppe28 based in Hamburg, Germany. Leah Nash is an award winning, Portland-based photographer with a passion for documenting the everyday and the extreme, which she often finds are one and the same. Her work was published in distinguished magazines and newspapers including Mother